No Data
US Stock MarketDetailed Quotes
BJDX Bluejay Diagnostics
Watchlist
3.2200
-0.0100-0.31% Close 12/01 16:00 ET
3.2200High3.1600Low1.04KVolume
3.1700Open3.2300Pre Close3.32KTurnover0.13%Turnover RatioLossP/E (TTM)3.99MMarket Cap17.600052wk HighLossP/E (Static)1.24MShares2.900052wk Low0.77P/B2.55MFloat Cap125.0000Historical High--Dividend TTM790.68KShs Float2.9000Historical Low--Div YieldTTM1.86%Amplitude3.1960Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About Bluejay Diagnostics Company
Bluejay Diagnostics, Inc. operates as a diagnostic company. It develops and markets minimally-invasive Point-of-Care diagnostics tests and devices that provide patients and providers with access to affordable and timely healthcare. It focus is on the infectious disease, inflammation, and oncology markets. The company was founded by Svetlana Dey and Dey Indraneil on March 20, 2015 and is headquartered in Acton, MA.
Revenue Breakdown
Business
Currency:USD
2022/12/31
Stock NameRevenueRatio
Single Segment249.04K100.00%
News
Bluejay Diagnostics Q3 EPS $(2.08) Up From $(3.00) YoY
Bluejay Diagnostics (NASDAQ:BJDX) reported quarterly losses of $(2.08) per share. This is a 30.67 percent increase over losses of $(3.00) per share from the same period last year.
BlueJay Diagnostics Names Frances Scally As CFO, Replacing Kenneth R. Fisher
https://www.sec.gov/ix?doc=/Archives/edgar/data/1704287/000101376223000463/ea186147-8k_bluejay.htm
ACST, TRT and CNTX Among Mid-day Movers